0
Article |

Biochemical Studies on the Metabolism of Griseofulvin

EARL G. Mc NALL
Arch Dermatol. 1960;81(5):657-661. doi:10.1001/archderm.1960.03730050013003.
Text Size: A A A
Published online

Introduction  Since the discovery of and the subsequent use of griseofulvin in the systemic treatment of dermatophyte infection, many observations have been made concerning this antibiotic's effect on both the host and the infectious organism. It seems clear that orally administered griseofulvin inhibits the growth of dematophytes in vivo without inducing significant adverse effects an either man or experimental animals.2-6 When this antifungal antibiotic is injected intravenously in rats at approximately ten times (100-200 mg/kg.) the oral therapeutic dosage, arrest of mitosis is observed in metaphase.7 In this respect griseofulvin resembles colchicine. Similar effects by griseofulvin have been reported in plant cells.7This paper presents data on the blood and serum levels of mice following a single oral dose of griseofulvin, chromatographic and spectrophotometric assay techniques for this antibiotic, and the partial reversal of griseofulvin activity by purines, pyrimidines, and their nucleotides.

Methods 

Assays Utilizing Tritium-Labeled Griseofulvin.— 

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 48

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs